Imaging of the Distribution of 90Y-Ibritumomab Tiuxetan in Bone Marrow and Comparison with Pathology-Reference-Cited by-同舟云学术

Imaging of the Distribution of 90Y-Ibritumomab Tiuxetan in Bone Marrow and Comparison with Pathology

Published:2007-10 Issue:5 Volume:22 Page:665-671
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Coulot Jeremy¹²³,Camara-Clayette Valérie⁴,Ricard Marcel¹²³,Lavielle Frédéric¹²³,Velasco Valérie⁵,Drusch Françoise⁵,Bosq Jacques⁵,Schlumberger Martin²,Ribrag Vincent⁴⁶

Affiliation:

1. Department of Physics, Institut Gustave-Roussy, Villejuif, France

2. Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave-Roussy, Villejuif, France

3. Department of Physics Imaging Research Unit, Institut Gustave-Roussy, Villejuif, France

4. Department of INSERM U790, Institut Gustave-Roussy, Villejuif, France

5. Department of Pathology, Institut Gustave-Roussy, Villejuif, France

6. Department of Hematology, Department, Institut Gustave-Roussy, Villejuif, France

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2007.355

Reference16 articles.

1. Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

2. Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

3. Additional Radiation Absorbed Dose Estimates for Zevalin™ Radioimmunotherapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of Ibritumomab as Radionuclide Therapy Agent;Resistance to Targeted Anti-Cancer Therapeutics;2018

2. Radioimmunotherapy for B-Cell Non-Hodgkin Lymphoma;Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer;2010-07-15